NEW YORK (GenomeWeb News) – Nuclea Biotechnologies and the College of Nanoscale Science & Engineering (CNSE) of the State University of New York on Thursday announced a $1 million research partnership to develop and commercialize a high-throughput nanochip to analyze biomarkers associated with cancer.

The partnership is aimed at accelerating the diagnosis and treatment of breast, colon, prostate, and other cancers, they said. The partners plan to develop a nanochip based on Nuclea's antibody protein analysis chip for fatty acid synthase analysis.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.